Japanese pharmaceuticals Loading... : Investor Sentiment and Bull/Bear Views

Loading chart...
Top Calls

No data yet

Price change since each call, adjusted for long/short direction. Results calculated:

Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
All Content
Source feeds
Buzzberg Top 50
All market capsNo capitalization filter
200 B and aboveMega
10 B to 200 BLarge
2 B to 10 BMid
0 to 2 BSmall
Custom
Enter market cap range in B USD
All directions
▲ Long
▼ Short
⛔ Avoid
✂ Close
◦ Others
Any score
LOW+
MED+
HIGH
? ?
04:10
Feb 09
Takaichi policy lifts Japan sectors
Takaichi's agenda is focused on moving Japan's economy forward by investing in areas such as pharmaceuticals, defense and shipbuilding, creating opportunities for U.S. and Japanese companies to collaborate. This makes those Japanese sectors levered to policy support and cross-border investment.
MED
04:10
Feb 09
David Boling Former Deputy Assistant U.S. Trade Representative for Japan… Bloomberg Markets
US-Japan deals lift key sectors
The U.S.-Japan investment agreement identifies semiconductors, pharmaceuticals, critical minerals and quantum computing as priority sectors. Deals in those areas are being discussed and should roll out soon ahead of Takaichi's U.S. trip, creating policy-driven tailwinds.
MED

About Japanese pharmaceuticals Investor Commentary

Across the available history and selected sources, Buzzberg tracks Japanese pharmaceuticals across 1 sources: 2 bullish vs 0 bearish calls from 2 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 2 total trade ideas tracked. Latest voices: Christopher LaFleur, David Boling.